General Information of Drug (ID: DMC8NAO)

Drug Name
ADXS-HPV Drug Info
Indication
Disease Entry ICD 11 Status REF
Cervical cancer 2C77.0 Phase 2 [1]
Cervical Intraepithelial neoplasia 2E66.1 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMC8NAO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VGX-3100 DMMQ2U9 Cervical Intraepithelial neoplasia 2E66.1 Phase 3 [3]
Tipapkinogene sovacivec DM5XRMA Cervical Intraepithelial neoplasia 2E66.1 Phase 2 [4]
CIGB-228 DMJFPK6 Human papillomavirus infection 1A9Y Phase 1 [5]
KITE-439 DMUB3H9 Cervical cancer 2C77.0 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human papillomavirus protein E7 (HPV E7) TT3CPZW VE7_HPV16 Not Available [2]

References

1 ClinicalTrials.gov (NCT02002182) Window of Opportunity Trial of ADXS 11-001 Vaccination Prior to Robotic Surgery of HPV-Positive Oropharyngeal Cancer. U.S. National Institutes of Health.
2 ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. Journal for ImmunoTherapy of Cancer, 2013, 1(Suppl 1):P231.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Immune therapy for human papillomaviruses-related cancers
5 Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011: 292951.
6 ClinicalTrials.gov (NCT03912831) Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers. U.S. National Institutes of Health.